Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic
Authors:
- 5 March 2010
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 30 (2) , 220-225
Abstract
The objectives of this retrospective cohort study are to evaluate the accuracy of pharmacogenetic warfarin dosing algorithms in predicting therapeutic dose and to determine if this degree of accuracy warrants the routine use of genotyping to prospectively dose patients newly started on warfarin. Seventy-one patients of an outpatient anticoagulation clinic at an academic medical center who were age 18 years or older on a stable, therapeutic warfarin dose with international normalized ratio (INR) goal between 2.0 and 3.0, and cytochrome P450 isoenzyme 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genotypes available between January 1, 2007 and September 30, 2008 were included. Six pharmacogenetic warfarin dosing algorithms were identified from the medical literature. Additionally, a 5 mg fixed dose approach was evaluated. Three algorithms, Zhu et al. (Clin Chem 53:1199–1205, 2007), Gage et al. (J Clin Ther 84:326–331, 2008), and International Warfarin Pharmacogenetic Consortium (IWPC) (N Engl J Med 360:753–764, 2009) were similar in the primary accuracy endpoints with mean absolute error (MAE) ranging from 1.7 to 1.8 mg/day and coefficient of determination R 2 from 0.61 to 0.66. However, the Zhu et al. algorithm severely over-predicted dose (defined as ≥2× or ≥2 mg/day more than actual dose) in twice as many (14 vs. 7%) patients as Gage et al. 2008 and IWPC 2009. In conclusion, the algorithms published by Gage et al. 2008 and the IWPC 2009 were the two most accurate pharmacogenetically based equations available in the medical literature in predicting therapeutic warfarin dose in our study population. However, the degree of accuracy demonstrated does not support the routine use of genotyping to prospectively dose all patients newly started on warfarin.Keywords
This publication has 14 references indexed in Scilit:
- Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of WarfarinJournal of General Internal Medicine, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- Estimation of Warfarin Maintenance Dose Based on VKORC1 (−1639 G>A) and CYP2C9 GenotypesClinical Chemistry, 2007
- Several-fold increase in risk of overanticoagulation by CYP2C9 mutationsClinical Pharmacology & Therapeutics, 2005
- The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood, 2005
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeThrombosis and Haemostasis, 2005
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin TherapyJAMA, 2002
- Human P450 metabolism of warfarinPharmacology & Therapeutics, 1997